Despite improvements in cardiovascular implantable electronic device (CIED) design,
application of timely infection control practices, and administration of antibiotic prophylaxis at …

Background—Periprocedural bridging with unfractionated heparin or low-molecular-weight
heparin aims to reduce the risk of thromboembolic events in patients receiving long-term …

Pacemakers, implantable cardiac defibrillators (ICDs), and cardiac resynchronization
therapy (CRT) devices are lifesaving treatments for a number of cardiac conditions. Device …

Pacemakers, implantable cardiac defibrillators, and cardiac resynchronization therapy
devices are potentially life-saving treatments for a number of cardiac conditions, but are not …

Background This guideline addresses the management of patients who are receiving
anticoagulant or antiplatelet therapy and require an elective surgery or procedure. Methods …

Background Many patients requiring pacemaker or implantable cardioverter–defibrillator
(ICD) surgery are taking warfarin. For patients at high risk for thromboembolic events …

Background—Dabigatran reduces ischemic stroke in comparison with warfarin; however,
given the lack of antidote, there is concern that it might increase bleeding when surgery or …

Thrombosis has long been recognized as a potentially lifethreatening complication in
children with congenital heart disease (CHD), children with acquired heart disease, and in …

Since the advent of the non-vitamin K antagonist oral anticoagulant (NOAC) agents, which
act as direct thrombin inhibitors or inhibitors of Factor Xa, clinicians are provided with …

Despite the clear net clinical benefit of oral anticoagulation (OAC) in atrial fibrillation (AF)
patients at risk for stroke, major bleeding events (especially intra-cranial bleeds) may be …